コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ncluding TDP-43 proteinopathy, tauopathy and alpha-synucleinopathy.
2 n postmortem brain tissue from patients with alpha-synucleinopathy.
3 and in situ studies of human specimens with alpha-synucleinopathy.
4 a key neurodegenerative mechanism underlying alpha-synucleinopathy.
5 2-tailed t test; P = .04) and more frequent alpha-synucleinopathy.
6 pecies generation, could be major players in alpha-synucleinopathy.
7 ERS could contribute to neurodegeneration in alpha-synucleinopathy.
8 oligomers in mouse and human brain with the alpha-synucleinopathy.
9 degeneration in Parkinson's disease (PD) and alpha-synucleinopathy.
10 mmals have different mechanisms to forestall alpha-synucleinopathy.
11 he formation of inclusions in PD and related alpha synucleinopathies.
12 herefore, MSA is included in the category of alpha-synucleinopathies.
13 ed to slow the progression of PD and related alpha-synucleinopathies.
14 n how it evades sHsp chaperone action in the alpha-synucleinopathies.
15 ogic hallmarks of Parkinson disease (PD) and alpha-synucleinopathies.
16 tential disease indicator for PD and related alpha-synucleinopathies.
17 ve diseases, collectively referred to as the alpha-synucleinopathies.
18 s for monomeric alpha-syn in PD and in other alpha-synucleinopathies.
19 constipation in Parkinson disease and other alpha-synucleinopathies.
20 of Lewy body inclusions in neurodegenerative alpha-synucleinopathies.
21 ation for the treatment of the yet incurable alpha-synucleinopathies.
22 ark lesions in Parkinson's disease and other alpha-synucleinopathies.
23 y to degrade alpha-synuclein in PD and other alpha-synucleinopathies.
24 ocessing and may modulate the progression of alpha-synucleinopathies.
25 uld be an effective therapy for PD and other alpha-synucleinopathies.
26 ration in Parkinson's disease (PD) and other alpha-synucleinopathies.
27 ions that contribute to neurodegeneration in alpha-synucleinopathies.
28 pathogenesis of Parkinson disease and other alpha-synucleinopathies.
29 r [RBD]) are common features of sleep in the alpha-synucleinopathies.
30 R-7 as a therapeutic target for PD and other alpha-synucleinopathies.
31 e-linked aggregation of alpha-Syn in various alpha-synucleinopathies.
32 on of alpha-syn inclusions in PD and related alpha-synucleinopathies.
33 erapies for PD and related neurodegenerative alpha-synucleinopathies.
34 hogenesis of Parkinson's disease and related alpha-synucleinopathies.
35 erative disorders, including tauopathies and alpha-synucleinopathies.
36 athogenesis of Parkinson's disease and other alpha-synucleinopathies.
37 enesis of Parkinson's disease (PD) and other alpha-synucleinopathies.
38 a significant factor in the pathogenesis of alpha-synucleinopathies.
39 transgenic mouse model of neurodegenerative alpha-synucleinopathies.
41 patients with Parkinson's disease and other alpha-synucleinopathies and demonstrated that NUB1, as w
42 ation between OH and cognitive impairment in alpha-synucleinopathies and discuss possible mechanisms
43 rotein epsilon status, presence of infarcts, alpha-synucleinopathy and neuronal loss in substantia ni
44 hat synphilin-1 can diminish the severity of alpha-synucleinopathy and play a neuroprotective role ag
45 nship between OH and cognitive impairment in alpha-synucleinopathies, and 'indirect-evidence studies'
48 h Lewy body disorders with autopsy-confirmed alpha synucleinopathy (as of Oct 1, 2015) who were previ
50 Here we describe a new Drosophila model of alpha-synucleinopathy based on widespread expression of
51 Lewy bodies, and multiple system atrophy are alpha-synucleinopathies characterized by filamentous alp
52 napse in dementia with Lewy bodies and other alpha-synucleinopathies, direct evidence for the precise
53 hese populations differ in when they exhibit alpha-synucleinopathies during PD pathogenesis, they cou
54 Noting that DMV neurons display extensive alpha-synucleinopathies earlier than SN dopamine neurons
56 OH and cognitive impairment in patients with alpha-synucleinopathies exists, but the underlying mecha
57 e screened the cerebella of 12 patients with alpha-synucleinopathies for neuropathological changes.
58 centre as a random effect, we observed that alpha-synucleinopathies, frontotemporal lobar degenerati
60 -binding protein 43 immunoreactive deposits, alpha-synucleinopathies, hippocampal sclerosis and prion
61 y could have prospect in the amelioration of alpha-synucleinopathy in PD and other Lewy body diseases
64 he brains of patients with neurodegenerative alpha-synucleinopathies, including Parkinson's disease.
65 vation of phospho-eIF2alpha, indicating that alpha-synucleinopathy is associated with abnormal UPR th
68 isk factors, imaging changes associated with alpha-synucleinopathy, or physical findings of parkinson
72 s with Alzheimer's disease and patients with alpha-synucleinopathy showed relatively lower burdens of
73 Urinary urgency and frequency are common in alpha-synucleinopathies such as Parkinson disease, Lewy
74 ntral catecholamine deficiency characterizes alpha-synucleinopathies such as Parkinson's disease.
75 onal inclusions more commonly found in other alpha-synucleinopathies such as Parkinson's disease.
77 auopathies, such as frontotemporal dementia; alpha-synucleinopathies, such as Parkinson's disease or
80 kin in alpha-synuclein-containing lesions in alpha-synucleinopathies, thereby challenging prior infer
81 of Lewy body disorder with autopsy-confirmed alpha synucleinopathy, we identified 49 (23%) patients w
82 aS transgenic (A53TalphaS Tg) mouse model of alpha-synucleinopathy, we show that disease onset in the
83 for dementia due to Alzheimer's disease and alpha-synucleinopathies, which suggests that these disor
84 aused defects in neuronal autophagy prior to alpha-synucleinopathy, which was associated with accumul
85 is facile, synchronized rapid-onset model of alpha-synucleinopathy will be highly valuable in testing
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。